Opening in 2026, TRI’s Translational Manufacturing facility will be Australia’s first on-demand production centre meeting rigorous cGMP standards for therapeutic products, enabling biotech, pharmaceutical and healthcare technology companies to accelerate development of next-generation treatments and devices.
Medical-grade cleanrooms, PC2-certified wetlabs and purpose-built office space empower growing companies to conduct their own manufacturing, quality testing and product development in one location. Supported by in-house technical experts and comprehensive training programs, these firms can seamlessly scale production across Phase I-III clinical trials while ensuring compliance with Australian and international regulation.
This transformative infrastructure at BRIJ removes a critical bottleneck in Australia’s commercialisation pathway, allowing innovators to advance promising discoveries – from biologics and cell-based treatments to RNA and plasmid DNA therapies – through clinical validation and into patient care with unprecedented speed and confidence.
* Artist impression
